focus -WSS

focus

author：hotspot 2025-09-29 19:58:39 - browse：3485

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the fourth quarter:

The Food and Drug Administration’s decision in June to grant conditional approval to a gene therapy for Duchenne muscular dystrophy was a watershed moment for the treatment of the neuromuscular disease, and a big win for its maker, Sarepta Therapeutics. Confirming the gene therapy’s benefit — and potentially broadening its use to include older boys — will be determined by a Phase 3 clinical trial that will read out later this quarter.

Pfizeris developing its own gene therapy for Duchenne in a fully enrolled Phase 3 study with final results expected in 2024. But before the verdict is revealed, Pfizer intends to conduct an interim analysis later this quarter. The most likely outcome of this early look will be a determination to continue the study to its completion. But surprises — including an early stop for overwhelming efficacy — can’t be ruled out.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare details structure of new drug price negotiation program
Next article： How to make Best Hospitals ratings actually useful for patients

explore

entertainment

WSS

Reporting on presidential health from Reagan to Trump and Biden

As pharma fights Medicare drug negotiation, hospitals, docs silent

Departing Stanford president retracts two papers

Obamacare plans could cover weight loss drugs

Australia’s approach to dialysis celebrates life

A new drug could help frostbite victims avoid its ravages

focus

focus

hotspot

Tori Bowie and the unacceptable rates of Black maternal death

Measles policy set amid Florida outbreak alarms vaccine proponents

DIEP, the 'gold standard' of breast reconstruction, is under threat

What do new weight loss drugs mean for bariatric surgery?

Affirmative action in medical school literally saved lives

Bipartisan group of lawmakers warns of a rising Chinese threat to U.S. biotech

The cancer drug shortage isn’t new — and neither are the solutions

How a symptom of dementia informs our understanding of creativity

After affirmative action ruling, medical educators look to 'holistic review'

Study finds new variant for Parkinson’s in African populations

hotspot

Appeals court upholds limits to abortion pill

Congress may force more Covid

Researchers tackle phage therapy hurdles for wider adoption

As AI regulations shape up, health tech startups beg for clarity

Abridge raises $150m as clinical notes automation market heats up

AstraZeneca bets AAV gene therapy will still deliver the goods

explore

entertainment

hotspot

focus